Most Read Articles
6 days ago
In patients with type 2 diabetes, obesity may be protective against vision-threatening diabetic retinopathy, a recent Korea study has shown.
Yesterday
The aromatase inhibitor anastrozole shows promise in the treatment of children with congenital adrenal hyperplasia, reducing bone age advancement without adversely affecting bone mineral density and visceral adipose tissue, as shown in a recent study.
Roshini Claire Anthony, 5 days ago

Men with metastatic hormone-sensitive prostate cancer (mHSPC) who receive testosterone suppression therapy may have a better survival outcome with the addition of enzalutamide over other non-steroidal anti-androgen (NSAA) therapies, according to the phase III ENZAMET* trial.

5 days ago
The use of opioids may have limited long-term efficacy in the management of chronic noncancer pain, reports a new study.

Ibrutinib-related atrial fibrillation common, predicted by left atrial volume index

6 days ago

Ibrutinib-related atrial fibrillation (IRAF) occurs more frequently than previously reported, with the left atrial volume index (LAVI) independently predicting such events, a study has found.

Researchers performed standardized monitoring in 53 consecutive patients (median age, 70 years; 74 percent male; median body mass index, 25 kg/m2) prior to and during ibrutinib therapy.

IRAF occurred in 14 patients (26 percent) after a median of 13 months, resulting in an incidence rate of 25.0 per 100 person-years. The cumulative incidence rate of IRAF was 21 percent at 6 months, 23 percent at 12 months and 38 percent at 24 months. The majority of events occurred in asymptomatic patients within a median time of 5.5 months.

Of note, the incidence of IRAF at 2 years was 15 times higher than the risk of atrial fibrillation observed in both the general population and chronic lymphocytic leukaemia patients not exposed to ibrutinib (p<0.0001).  

The risk of developing IRAF was significantly higher in the presence of LAVI ≥40 mL/m2 at treatment initiation. None of the patients on ibrutinib had major bleeding events, although the majority of patients with IRAF received anticoagulants.

The present data highlight the importance of performing standardized and close monitoring of asymptomatic patients in the first few months following initiation of ibrutinib, the researchers said. Furthermore, LAVI measurement may help identify patients at high risk and that anticoagulants could be considered in the absence of significant bleeding risk.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago
In patients with type 2 diabetes, obesity may be protective against vision-threatening diabetic retinopathy, a recent Korea study has shown.
Yesterday
The aromatase inhibitor anastrozole shows promise in the treatment of children with congenital adrenal hyperplasia, reducing bone age advancement without adversely affecting bone mineral density and visceral adipose tissue, as shown in a recent study.
Roshini Claire Anthony, 5 days ago

Men with metastatic hormone-sensitive prostate cancer (mHSPC) who receive testosterone suppression therapy may have a better survival outcome with the addition of enzalutamide over other non-steroidal anti-androgen (NSAA) therapies, according to the phase III ENZAMET* trial.

5 days ago
The use of opioids may have limited long-term efficacy in the management of chronic noncancer pain, reports a new study.